Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Exanthema × Erlotinib Hydrochloride × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 140 Lung Neoplasms 51 Pancreatic Neoplasms 30 Non-Squamous Non-Small Cell Lung Cancer 18 Neoplasms 15 Adenocarcinoma of Lung 14 Head and Neck Neoplasms 13 Glioblastoma 13 Gliosarcoma 12 Breast Neoplasms 11 Brain Neoplasms 11 Neoplasm Metastasis 9 Carcinoma, Hepatocellular 9 Adenocarcinoma, Bronchiolo-Alveolar 9 Squamous Cell Carcinoma of Head and Neck 8 Carcinoma, Squamous Cell 7 Carcinoma, Renal Cell 7 Astrocytoma 6 Oligodendroglioma 5 Carcinoma 5 Urinary Bladder Neoplasms 4 Liver Neoplasms 4 Glioma 4 Esophageal Neoplasms 4 Colorectal Neoplasms 4 Adenocarcinoma 4 Recurrence 3 Rectal Neoplasms 3 Prostatic Neoplasms 3 Ovarian Neoplasms 3

Interventions

benralizumab 1 Triamcinolone Acetonide 1 Tetracycline 1 Sirolimus 1 Panitumumab 1 Minocycline 1 Irinotecan 1 IFL protocol 1 Hydrocortisone 1 Gels 1 Fulvestrant 1 Erlotinib Hydrochloride 1 Dapsone 1 Clindamycin 1 Anti-Bacterial Agents 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00473083 2017-04-04

LUTRAERL

British Columbia Cancer Agency

Phase 2 Completed

150 enrolled 13 charts

Exanthema, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡